Canaccord lowered the firm’s price target on Fractyl Health (GUTS) to $6 from $12 and keeps a Buy rating on the shares. The target was lowered after the firm updated its model for Q2 results and a subsequent equity offering while noting key timelines remain on track.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health’s Earnings Call: Strategic Gains Amid Financial Challenges
- Fractyl Health Reports Q2 2025 Financial Results and Progress
- Fractyl Health, Inc.: Promising Developments and Strategic Focus Justify Buy Rating
- GUTS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biotech Alert: Searches spiking for these stocks today